The International AIDS Vaccine Initiative (IAVI) has launched a unique initiative to develop HIV vaccine. Under this initiative, the first step to make a special type of powerful protein effective in the prevention of HIV has been announced to start the first phase of testing. IAVI's President and CEO Mark Fenberg said, "A new method is needed to prevent HIV infection in the world."
Phineburg, a MD and PhD degree, said, "Fortunately, a new generation of clinical trials of HIV immunogenant (medicine) is being started." He said that it is being developed using highly sophisticated and excellent vaccine science Is being offered as an example in the form of vaccine, which aims to create special antibodies to protect against HIV infection. Is.
Phineburg said, "Our goal is to make better vaccines for prevention of HIV infection. Keeping this goal in mind, this clinical trial has started. "This drug has been developed in the laboratory of Dr. William Seif, Director of Vaccine Design of Neutralizing Antibody Center (NAC) of IAV. Dr. Seif said, "Our goal in this test is to prove that it is possible to get response from specifically targeted 'B' cells."